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HPV is the most common sexually transmitted infection in the US, and it can lead to minor 
health problems such as genital warts and serious problems like cancer in men and women. HPV 
vaccination can effectively prevent HPV-related cancers and is recommended by ACIP to 
individuals aged 9 - 26. HPV vaccine uptake is low among adolescents and young adults in the 
US. College students have a window of opportunity to catch up with their HPV immunizations, 
and are often uninformed about HPV, the HPV vaccine, their eligibility to receive the HPV 
vaccine, and where they can obtain the HPV vaccine. An online educational video about HPV 
was produced for Seattle University (SU) students with the purpose of informing them about 
HPV and prompting unvaccinated students to get vaccinated. The video was placed in an online 
survey containing pre- and post-video questionnaires testing viewers’ HPV knowledge and self-
reported likelihood to get vaccinated. Viewers’ self-reported likelihood to vaccinate and correct 
answers to HPV knowledge questions increased in the post-video questionnaire. Educational 
interventions such as the one evaluated in this project can improve young adults’ HPV 












 Human papillomavirus (HPV) is the most common sexually transmitted infection in the 
United States, and it can lead to genital warts and cancers of the cervix, vagina, anus, penis, 
mouth and throat (Centers for Disease Control and Prevention [CDC], 2021). Of these, only 
cervical cancer is screened, while other HPV-related cancers may go undetected until they cause 
significant health problems (CDC, 2020c). Immunization against HPV effectively prevents 
infection and thereby HPV-related cancers and is safe. The Advisory Committee on 
Immunization Practices (ACIP) recommends routine vaccination against HPV at age 11 - 12, but 
immunization can begin as early as age 9, and catch-up vaccination is recommended until age 26 
for men and women (Meites et al., 2019).  The vaccine is given in a series of two doses for 
individuals younger than 15, and three doses for those older than 15 or immunocompromised and 
between ages 9 and 26 (Meites et al., 2016).  
 Although the HPV vaccines are safe (Donahue et al., 2019) and have significantly 
decreased the incidence of HPV infection, genital warts and precancerous lesions in the cervical 
epithelium (Jach et al, 2016), only 48% of adolescents aged 13 - 15 had completed the HPV 
vaccination series by 2018 in the United States (US Department of Health and Human Services 
[DHHS], n.d.). That same year, only 41% of Washington State adolescents aged 13 - 17 were up 
to date on their HPV immunizations (Washington State Department of Health, n.d.). These 
numbers are well below the Healthy People 2020 and Healthy People 2030 target of 80% 
coverage among youth aged 13 - 15 (DHHS, n.d.). Data from the National Health Interview 
Survey (NHIS) showed that in 2014, among adults aged 19 - 26, only 40% of females and 8% of 
males had received at least one dose of the HPV vaccine, and a substantial proportion of these 
young adults had received their first dose after age 19 (Williams et al., 2016).  
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 With less than 50% of adolescents completing their HPV immunizations until 2018, it 
can be inferred that a significant number of young adults in 2021 have missed their HPV 
immunizations in adolescence. A proportion of these unvaccinated adults may be found in 
college campuses, where they can be approached and informed about HPV and the HPV vaccine. 
Colleges and universities are a convenient place to search for unvaccinated young adults who 
still have time to get their HPV immunizations. The purpose of this project was to inform Seattle 
University (SU) students about HPV and HPV-related cancers, as well as the HPV vaccine with 
an educational video available online. It was expected that such information would prompt at 
least some unvaccinated students to get their HPV immunizations. A related aim was to evaluate 
the effectiveness of the video for improving viewers’ HPV knowledge and increasing their 
intentions to vaccinate against HPV. 
Theoretical framework - The precaution adoption process model 
 The precaution adoption process model (PAPM) asserts that before adopting protective or 
preventive health behaviors, individuals pass through an orderly sequence of discrete cognitive 
stages (Weinstein, 1988). The stages in the process are “unaware of the issue,” “aware of the 
issue but not personally engaged,” “engaged and deciding what to do,”  “decided to act but not 
yet having acted,” “acting,” and “maintenance” (Weinstein & Sandman, 1992). An additional 
stage, that of “decided not to act '' branches off from the stage of “engaged and deciding what to 
do.” Figure 1 depicts the stages of the PAPM as it pertains to HPV vaccine uptake. Weinstein 
(1988) proposes that “[individuals] at different stages in the precaution adoption process behave 
in qualitatively different ways and the kinds of interventions and information needed to move 
people closer to action will vary from stage to stage” (p. 358). Moreover, transitions from one 
stage to the next present barriers that must be overcome until an individual acts on an issue 
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(Weinstein, 1988). Taking HPV vaccination as an example, an individual may be unaware of 
HPV and the HPV vaccine (first stage). Then that individual learns about the existence of HPV, 
but will be unengaged by the issue (second stage). As the individual learns more about HPV and 
the HPV vaccine he starts deciding whether to get vaccinated (third stage), and he may either 
decide against vaccination or decide to get the vaccine (fourth stage). According to the PAPM, at 
this stage there may be significant barriers for the individual to overcome before getting the first 
dose of the HPV vaccine, i.e., “acting on the issue” (fifth stage). The individual, for instance, 
may not have insurance, requiring him to pay out of pocket for his vaccination, or he may have 
difficulty finding a place where the vaccine is given, or he may be extremely busy with other life 
demands that hinder him from acting on his decision. According to Weinstein, a reminder, or cue 
to action, or providing key information on how to make it easier to act (for instance, by 
providing information on convenient locations where the HPV vaccine can be obtained) may 
help the individual overcome barriers and get his first dose of the HPV vaccine. The individual 
may have to again overcome barriers to get his second and third doses of the HPV vaccine 
(maintenance stage).  
Furthermore, an individual’s progression through the stages of the PAPM, especially 
arriving at the decision to act, is contingent upon that individual’s belief about his vulnerability 
to harm (Weinstein, 1988). For example, before deciding to adopt a protective behavior such as 
getting the HPV vaccine, an individual must believe that he is susceptible to HPV infection, that 
the infection will significantly harm him, and that the HPV vaccine will effectively protect him 
from HPV infection and its associated harms. In the PAPM, beliefs of personal susceptibility to 
harm are also developed in discrete stages (Weinstein, 1988). Using HPV as an example, the first 
stage is learning that HPV exists (“I have heard about HPV”), the second stage is believing that 
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there is a significant likelihood that others are affected by HPV (“HPV infection affects quite a 
few people”), and the third stage is for the individual to believe that he is personally susceptible 
to HPV infection and its consequences (“I could get infected with HPV and end up with genital 
warts or cancer”). In similar fashion, an individual must develop, step by step, the belief that a 
preventive behavior is effective in protecting him from harm (Weinstein, 1988), e.g., going from 
“I have heard about the HPV vaccine” to “I believe the HPV vaccine is effective in preventing 
HPV infection” to “I believe the HPV vaccine will protect me from HPV infection.”  
Progression along the stages of belief development is influenced by several factors 
including biases, information from media and acquaintances, and personal experience. One 
significant barrier that Weinstein (1988) identifies for individuals passing from the stage of 
“believing an issue poses risk for others” to the stage of “believing the issue poses personal risk” 
is optimistic bias, a belief that our own risk is less than others’ risk. Optimistic biases may be 
reinforced by incorrect information, cognitive errors, or a desire to avoid anxiety (Weinstein, 
1988). Personal experience, correct information about risk factors, and knowing about 
precautions taken by peers can decrease optimistic biases, but general facts about a hazard (e.g., 
human papillomaviruses are double-stranded DNA viruses, the global burden of HPV infection, 
or how HPV causes cancer) are unlikely to help individuals move from one belief stage to the 
next (Weinstein, 1988). Weinstein (1988) further notes that although individuals consider their 
susceptibility to a hazard, the magnitude of the harms caused by a hazard, and the cost and 
benefits of a preventive measure, people often arrive at a conclusion that a threat is “serious” 
based on notions of seriousness acquired from acquaintances and the media rather than a 




Other factors influencing people’s decisions and actions along the precaution adoption 
process include time (the time it takes for people to arrive at beliefs and make decisions), 
uncertainty (the costs of getting a vaccine are certain and immediate, but the benefits are a matter 
of probability and often are appreciated after a long time), and how an issue is framed 
(Weinstein, 1988). For example, presenting HPV vaccination as a measure to prevent cervical 
cancer may lead men to believe HPV is a female problem, but presenting HPV as a cause of 
genital warts and non-cervical cancers may help men realize they are susceptible to it. 
Therefore, when designing an educational intervention about HPV for college students, it 
must be considered that individuals will be at different stages in their decision-making process, 
that each individual will need a different message depending on his stage in the precaution 
adoption process, and that messages need to be properly framed so individuals can see how they 
are personally susceptible to HPV, how serious the matter is, and how the HPV vaccine will 
benefit them personally. 
Literature Review 
 It is estimated that each year in the United States 35,900 cases of cancer can be attributed 
to HPV infection, and immunization against HPV could prevent more than 90% of these cancers 
in both men and women (CDC, 2020b). It is important to distinguish between HPV-associated 
cancers and HPV-attributable cancers. HPV-associated cancers are cancers found at anatomic 
sites susceptible to HPV infection, such as the cervix vagina, vulva, penis, anus, and oropharynx 
(CDC, 2020a). The number of HPV-attributable cancers is estimated by multiplying the number 
of cancer cases of a particular anatomic site by the proportion of cancer tissue specimens, from 
the same anatomic site, where HPV is detected (CDC, 2020a). To estimate the proportion of 
cancers attributed to HPV prior to the introduction of the HPV vaccine, Saraiya et al. (2015) 
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collected tissue specimens from several cancer registries in the US and tested each specimen for 
HPV DNA. The tissue samples came from patients diagnosed between 1993 and 2005, before 
HPV vaccination was recommended in the US. In this genotyping study, it was estimated that 
91% of cervical cancers, 69% of vulvar cancers, 75% of vaginal cancers, 91% of anal cancers, 
63% of penile cancers, and 70% of oropharyngeal cancers are attributable to HPV of any type. 
Saraiya et al. also determined the type or HPV in each HPV positive sample, and found that of 
all HPV positive cervical cancers, 89% were attributable to HPV types 16, 18, 31, 33, 45, 52 and 
58, the oncogenic HPV types covered by the 9-valent HPV vaccine currently available in the US. 
Similarly Saraiya et al. found the same vaccine-type HPV genotypes in 92%, 98%, 96%, 90% 
and 94% of HPV positive vulvar, vaginal, anal, penile and oropharyngeal cancers respectively.  
Although this study did not include any samples from the Washington State Cancer Registry, its 
findings were used in the discussion that follows to estimate the number of HPV-attributable 
cancer cases in Washington State.  
 Data from the Washington State Cancer Registry indicate that between 2013 and 2017 
there were an average of 248 annual cases (6.8 per 100,000 population) of cervical cancer, 1084 
annual cases (12.9 per 100,000 population) of oropharyngeal cancer, and 304 annual cases (7.4 
per 100,000 population) of vulvar cancer (Washington State Department of Health, 2020). Using 
the HPV DNA detection results from the aforementioned genotyping study (Saraiya et al., 2015), 
it can be estimated that in Washington State between 2013 and 2017 there were on average 224 
annual cases of cervical cancer, 760 annual cases of oropharyngeal cancer, and 209 annual cases 
of vulvar cancer attributable to HPV infection. If immunization against HPV can prevent at least 
90% of HPV-attributable cancers (CDC, 2020b), a fully immunized population would have 
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decreased the annual number of HPV-related cancers by at least 1,073 cases, as this estimate 
does not include the number of penile and anorectal cancers in Washington.   
 The 9-valent HPV vaccine currently available in the US not only prevents infection with 
the oncogenic HPV types 16, 18, 31, 33, 45, 52 and 58, but also HPV types 6 and 11, which 
cause an estimated 90% of anogenital warts (Braaten & Laufer, 2008; Cox & Palefsky, 2020). 
Because a diagnosis of anogenital warts is not reportable to public health authorities, it is 
difficult to find precise incidence and prevalence statistics. However, prior to the introduction of 
the HPV vaccine it was estimated that one million new cases of anogenital warts were diagnosed 
annually in the US (Braaten & Laufer, 2008). Thus, with a fully vaccinated US population, it can 
be estimated that 900,000 cases of anogenital warts can be prevented each year. 
 Genital HPV infections are highly prevalent in the US. A study that used data from the 
National Survey of Family Growth (NSFG) estimated that before introduction of the HPV 
vaccine in the US, men and women had 80% probability of acquiring HPV infection by age 45 
(Chesson et al., 2014 - STD). Between 2003 and 2006, before the ACIP recommendations for 
vaccinating adolescent women against HPV, the prevalence of genital infection with any type of 
HPV was estimated by the National Health and Nutrition Examination Survey (NHANES) to be 
42% among non-institutionalized women aged 14 - 59 (Hariri et al., 2011). Prevalence of high-
risk (i.e., oncogenic or cancer-causing) HPV types was 29%, and that of low risk (i.e., non-
oncogenic, including those causing warts) HPV types was 28.5% (Hariri et al., 2011). Women 
aged 20 - 24 had the highest prevalence of high-risk (43.4%), and low risk (35.5%) HPV types 
(Hariri et al., 2011). In women 14 - 19 years old, it was found from NHANES data that 
prevalence of HPV types covered by the quadrivalent vaccine (4vHPV) decreased from 11.5% 
between 2003 and 2006 to 3.3% between 2011 and 2014, after the introduction of HPV 
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vaccination in the US (Oliver et al., 2017). Among 20 - 24 year-old women, prevalence of 
4vHPV types (HPV types 6, 11, 16 and 18) decreased from 18.5% between 2003 - 2006 to 7.2% 
between 2011 - 2014 (Oliver et al., 2017).  
 Because of low vaccine uptake each year, multiple cohorts of unvaccinated young adults 
have accumulated since 2006, when ACIP recommended HPV vaccination for all girls aged 11 - 
12 (Williams et al., 2017). It is estimated that in 2015 in the US, more than 9 million women 
aged 19 -26 and almost 14 million men in the same age range were unvaccinated (Williams et 
al., 2017). Evidence on the effectiveness of catch-up HPV immunization in women older than 20 
years is conflicting. Some studies (Silverberg et al., 2018) have found a significant decrease in 
risk of developing high grade cervical lesions in women who get their first dose of HPV vaccine 
between ages 14 - 20, but not for women first vaccinated at age 21 or older. Other studies 
(Castellsagué, et al., 2011) have found that the quadrivalent HPV vaccine is highly efficacious in 
preventing persistent infection with vaccine-type HPV, high grade cervical precancerous lesions, 
and external genital lesions in women aged 24 - 45. The rationale for current ACIP immunization 
recommendations in young adults is that most sexually active women have not been infected 
with both  HPV 16 and 18 (the most common oncogenic types targeted by the vaccines), and 
most young adults can benefit at least partially from vaccination (Williams et al., 2017; 
Markowitz et al., 2014). 
 Among college students, surveys have consistently found HPV vaccine uptake well 
below the Healthy People 2020 target of 80%, with lower immunization rates in males than in 
females (Barnard et al., 2017; Koplas et al., 2019; LaJoie et al., 2018; Ragan et al., 2018 ). 
Attempts have been made to assess knowledge of and attitudes toward HPV vaccination in the 
general adult population and young adults, and to identify barriers and facilitators of vaccination 
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against HPV (Fontenot et al., 2014; LaJoie et al., 2018; McBride & Singh, 2018, Ragan et al., 
2018).  
Studies have found varying levels of awareness of HPV and the HPV vaccine. In the 
2014 Health Information National Trends Survey (HINTS) conducted in a sample of the general 
adult population by the National Cancer Institute, only 60% of females and 44% of males 
reported being aware of HPV (McBride & Singh, 2018). In a survey of 383 college students, 
92% of females and 83% of males reported awareness of HPV, but less respondents of both 
sexes were aware of the HPV vaccine (Barnard et al., 2017). In several surveys respondents 
demonstrate knowledge of the link between HPV and cervical cancer, but knowledge of the link 
between HPV and non-cervical cancers is less common (Barnard et al., 2017; Fenkl et al., 2016; 
McBride & Singh, 2018).  
Other knowledge deficits and misperceptions about HPV and the HPV vaccine among 
significant numbers of college students include the feeling of not being at risk for exposure to 
HPV, not knowing HPV is the most common sexually transmitted infection, not knowing HPV 
can cause cancer, not knowing HPV can cause genital warts, thinking that condom use can 
prevent HPV transmission, not knowing that males can get HPV, not knowing the HPV vaccine 
can prevent cervical cancer, believing HPV is a female problem, believing that men who have 
sex with men do not need the HPV vaccine, confusing HPV with genital herpes, and believing 
the HPV vaccine is only for women (Garcia Jones, 2017; Poggio D’Errico et al., 2020; Fontenot 
et al., 2014; Barnard et al., 2017).  
Additionally, college students may not know they can get the HPV vaccine until age 26, 
or that the vaccine is offered at their campus clinic, nearby retail pharmacies and youth-friendly 
clinics (Kellogg et al., 2019). Surveyed college students also mention not being offered the HPV 
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vaccine, the inconvenience of making an appointment, time constraints, fear of side effects, cost, 
lack of insurance coverage, and their primary care clinician being in another town as reasons not 
to get the HPV vaccine or finish their immunization series once started (Fontenot et al., 2014; 
Ragan et al., 2018). In one survey, 27% of women and 2% of men reported not getting the HPV 
vaccine because their parents won’t allow them (Ragan et al., 2018). 
Studies have found that recommendation from a clinician is associated with higher rates 
of HPV vaccine uptake (Holman et al., 2014; Lau, 2012; Reiter, 2013). Parents and clinicians 
have a strong influence in college students’ decisions regarding HPV vaccination, as in one study 
94% of students who were encouraged by their parents got vaccinated, and almost 96% of those 
encouraged by both parents and clinicians got the HPV vaccine (Ragan et al., 2018). 
Additionally, in one survey 65% of respondents indicated they would get all HPV vaccine doses 
if offered free of charge (LaJoie, 2018). LaJoie et al. also found that respondents to their survey 
indicated vaccine recommendations by the CDC, having a HPV awareness program on campus, 
and messages focusing on cancer prevention rather than prevention of genital warts as a positive 
influence on getting the HPV vaccine. 
Consistent with Weinstein’s (1988) precaution adoption process model, young adults 
who believe are susceptible to HPV infection, believe the HPV vaccine effectively prevents 
cancer and who are not deterred by side effects are more likely to have received the HPV vaccine 
(Poggio D’Errico, 2020). Additionally, in a survey of adults aged 18 - 26 in Minnesota, it was 
found that participants with higher HPV literacy were more likely to have initiated or completed 
their HPV vaccination (Lee et al., 2017). 
Educational interventions in college campuses have improved students’ knowledge of 
HPV (Preston & Darrow, 2019; Staples et al., 2018). Preston & Darrow’s (2019) study also 
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demonstrated that the HPV knowledge gap between Hispanics and non-Hispanics present at 
baseline disappeared after their educational intervention was implemented.  
Although the precaution adoption process model states that reminders can sometimes be 
helpful in helping individuals act on their intentions to adopt health behaviors, studies on 
reminder/recall systems have found mixed results regarding improvement in HPV vaccine 
uptake or completion, with most studies finding no significant difference in completion rates 
between those who received reminders and those who did not (Kharbanda, 2011; Richman et al., 
2016; Richman et al., 2019; Szilagyi et al., 2020).  
In summary, HPV vaccine  uptake is well below Healthy People 2030 goals, young adults 
and adolescents have gaps in their HPV knowledge, educational interventions successfully 
increase knowledge of HPV and the HPV vaccine in young adults, and recommendation by a 
clinician increases the likelihood of HPV vaccine uptake. 
 Considering the findings of this literature review and the predictions of the precaution 
adoption process model, an educational video was produced to inform Seattle University (SU) 
students about HPV and the HPV vaccine, with the intention of increasing HPV knowledge and 
prompting unvaccinated students to get their HPV vaccines. Related aims of this project were to 
evaluate the effectiveness of the video in increasing HPV knowledge and in increasing the self-
reported likelihood of vaccine uptake among unvaccinated students. Additionally, participants’ 
baseline knowledge of HPV and HPV vaccine uptake were measured and compared between 
males and females as well as nursing and non-nursing students. An attempt was made to 







A nine-minute educational video on HPV was made in the form of an interview between 
a young obstetrics & gynecology physician and the principal investigator (PI) in the role of a 
registered nurse. The physician would answer questions pertaining to the following key 
messages aimed at college students: 
●  HPV is the most common sexually transmitted infection (STI) in the United States. 
● HPV can cause cancers of the throat, mouth, cervix, vulva, penis, and anus, as well as 
genital warts. 
●  Both men and women are susceptible to HPV and its related cancers. 
●  Any skin-to-skin or mucosal contact can transmit HPV. 
● Each new sex partner increases the risk of getting HPV. 
● HPV infections are often asymptomatic, and a person could be spreading the disease 
without knowing it. 
● The HPV vaccine is safe and decreases the risk of getting HPV. 
●  Men and women aged 11 – 26 should get vaccinated. 
● The HPV vaccine is only one preventive measure to protect health. People need to use 
birth control to prevent pregnancy, and condoms to prevent other STIs such as HIV. 
● Women who are vaccinated against HPV still need to screen for cervical cancer starting 
at age 21. 
● The HPV vaccine protects against the nine most common HPV types that cause cancers 
and genital warts. 
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After the interview, the principal investigator summarized the key messages from the 
interview and provided information on where to obtain the HPV vaccine. English subtitles were 
added to the video, which can be viewed at https://youtu.be/HQGD9mwVr2E. 
Evaluation of the intervention 
 The evaluation of the intervention aimed to answer two main questions: 1) Does viewers' 
knowledge about HPV and the HPV vaccine change after viewing the video? and 2) Among 
unvaccinated viewers, does self-reported likelihood to vaccinate change after viewing the video? 
Additionally, an attempt was made to compare post-intervention changes in likelihood to 
vaccinate between groups at different stages of the precaution adoption process. 
To evaluate changes in HPV knowledge and likelihood to vaccinate, the video was placed 
in the middle of an online anonymous survey. Appendix 1 lists the survey questions in detail. 
The first 25 questions of the survey (pre-video quiz) tested participants’ knowledge about HPV 
and the HPV vaccine. There were three answer options for the quiz question: True, false, and I 
don’t know. Next there were questions about participants’ gender, sex at birth, field of study 
(nursing or non-nursing), HPV vaccination status, and participants’ likelihood to vaccinate 
against HPV. The answer options for likelihood to vaccinate were in the form of Likert scale, 
with the options “very likely,” “likely,” “undecided,” “unlikely” and “very unlikely.”  
Demographics questions were kept to a minimum in order to make the survey as brief as 
possible and increase the likelihood that participants finish the survey once they start. The 
questions regarding gender, sex at bitrth, and whether participants are nursing students were 
included because it was anticipated that female students and nursing students would differ in 
their vaccination rate and knowledge of HPV from male and non-nursing students, respectively. 
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The last question before the video asked participants’ stage of decision-making about 
HPV vaccination, as described by the precaution adoption process model (Weinstein, 1988), that 
is, whether they are unaware of the issue (stage 1), unengaged (stage 2), deciding (stage 3), 
decided not to vaccinate (stage 4), decided to vaccinate (stage 5), acting on the issue (stage 6), or 
in maintenance (stage 7). Figure 1 describes the stages of the precaution adoption process model 
as it pertains to vaccinating against HPV. The answer options for this question, which was 
borrowed from a survey composed by Barnard et al. (2017), were: 
● I never seriously thought about getting the HPV vaccine 
● I have seriously thought about getting the HPV vaccine, but decided not to get it 
● I have seriously thought about getting the HPV vaccine, but have not thought about it in 
the last 6 months 
● I am seriously thinking about getting the HPV vaccine sometime within the next 6 
months 
● I plan to get the HPV vaccine within the next month 
 After this question, the online survey would direct participants to watch the video. A 
timer was programmed in the survey to ensure participants watch the entire video before moving 
on to the next question. Unfortunately, this was done after several participants had taken the 
survey and it came to the attention of the PI that a few participants had completed the survey in 
extremely short amounts of time, suggesting they had skipped the video. 
After the video, participants would see the same 25 HPV knowledge questions they 
answered before viewing the video, followed by one question on their likelihood to get the HPV 
vaccine/finishing their immunization series (answer choices were “extremely likely,” “somewhat 
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likely,” “uncertain,” “somewhat unlikely” and “extremely unlikely”), and an additional question 
asking how much they thought they had learned about HPV from the video. 
The survey questions came from two sources. The HPV and HPV vaccine knowledge 
questions were borrowed from a validated survey composed by Perez et al. (2016), who in turn 
included 16 questions from Waller et al.’s (2013) scale. Questions pertaining to likelihood of 
getting the vaccine and stage in the precaution adoption process were from an instrument 
composed by Barnard et al. (2017), which was not validated at the time of this writing.  
The online survey was published using Qualtrics, the preferred online survey platform at 
Seattle University. A website containing information about this project was made, and a link to 
the survey was included in the website. The website’s URL was shared with potential 
participants. Survey data was stored in secure Qualtrics servers and deleted once analysis was 
complete. The survey was available online from January to March 2021. 
Setting 
The project was implemented at Seattle University (SU), a small private university in the 
Capitol Hill neighborhood of Seattle, WA. SU draws students from the entire United States as 
well as international students. SU has both graduate and undergraduate students, some of whom 
live on campus, and some of whom get their healthcare at the university’s clinic. Full time 
undergraduate students are required to have health insurance. Seattle University offers two 
health-related programs for undergraduate students, nursing and diagnostic ultrasound. 
Ethical requirements and informed consent 
This project was reviewed by the Institutional Review Board (IRB) of Seattle University; 
it was deemed to be “Not Human Subjects Research” (NHSR), and thus exempt from IRB  
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review. Upon clicking on the link to the survey, participants would see the informed consent 
question, and in order to see the survey questions they would need to indicate they voluntarily 
choose to participate in the survey. IRB documentation is included in appendix 2. 
Recruitment and Participants 
Any SU student aged 18 - 26 was eligible to participate in the survey. The URL of the 
project’s website was posted on the website of SU’s Student Health Center. To attract more 
participants, the Dean of the College of Nursing was asked to distribute the survey link to all 804 
graduate and undergraduate nursing students enrolled in Winter 2021. Additionally, instructors 
of undergraduate classes in physics, criminal justice, history, Japanese language, accounting, 
geography, psychology and political science were asked to distribute the survey link to their 354 
students. As an incentive, participants who finished the survey had the option of entering a raffle 
to win a $25 Amazon gift card. Some of the instructors who were contacted offered extra credit 
points to students who completed the survey. 
Stakeholders in this project included the survey participants, SU Student Health Center 
clinicians and staff, College of Nursing Dean and faculty, instructors who distributed the survey 
link to their students, and the principal investigator, who conducted this project as a graduation 
requirement. 
Measures 
The measures evaluated in the survey included: 
● HPV and HPV vaccine knowledge, scored by assigning one point to each question 
answered correctly in the pre-video and post-video quizzes, which were identical. A 
maximum of 25 points was possible in each quiz. 
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● Self-reported likelihood to get HPV vaccine (for unvaccinated respondents) prior to 
watching the video, measured with a Likert scale including very unlikely, unlikely, 
undecided, likely, and very likely. 
● Self-reported likelihood to get the remainder doses of HPV immunization (for those who 
had incomplete HPV immunization) prior to watching the video, measured with a Likert 
scale. 
● Self-reported likelihood to find out HPV immunization status and get vaccinated (for 
those who did not know their immunization status) prior to watching the video, measured 
with a Likert scale. 
● Self-reported likelihood to get the HPV immunization or finish the series after watching 
the video, measured with a Likert scale. 
Statistical analysis 
 To maximize the use of data obtained, two main statistical analyses were made. In the 
first analysis, the baseline analysis, descriptive statistics were used to obtain the average baseline 
HPV knowledge score and the proportion of respondents who were fully vaccinated against HPV 
as well as those who had received at least one dose of the vaccine. This analysis included all 
responses that were complete at least up to the video. Surveys that were completed in an 
unreasonably short amount of time (less than one minute for those complete only up to the video, 
and less than 11 minutes for those completed entirely, i.e., less than two minutes spent 
responding to questions, assuming the nine-minute video was viewed entirely) were excluded 
from analysis.  
 The second analysis included only surveys that were completed entirely in at least 11 
minutes (two minutes spent responding to questions, assuming the video was viewed entirely). 
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This analysis replicated that of an interventional study by Staples et al. (2018). The authors of 
this study implemented an educational intervention at four different colleges and administered 
pre- and post-intervention surveys, much like in this project, with the difference that the 
intervention and the surveys were done in person. Also, Staples et al. tested statistical 
significance with paired t-tests, whereas in this study the Wilcoxon signed rank test, a more 
conservative test, was used. Unlike paired t-tests, the Wilcoxon signed rank test can be applied to 
small samples that are not distributed normally (Marin & Hamadani, 2018). The pre-video and 
post-video HPV knowledge scores were compared and statistical significance was tested with the 
Wilcoxon sign rank test. Additionally, the percentage of correct responses for each HPV 
knowledge question was compared between the pre- and post-video questionnaires.  
Pre- and post-video intention to vaccinate, intention to complete HPV immunization 
series, and intention to find out immunization status and take action were combined into a single 
measure, because each of the measures applied to small mutually exclusive subgroups in the 
sample. Thus, a single measure, the “intention to act on the issue” measure was created, which 
included one relatively large subgroup of the total sample, composed of respondents who were 
either unvaccinated, partially vaccinated, or uncertain of their vaccination status. The pre-video 
“intention to act on the issue” measure was compared to the post-video “intention to act on the 
issue” measure and statistical significance was tested with the sign test. The sign test (which 
unlike the Wilcoxon sign rank test ignores the magnitude of each respondent’s change) was used 
here because unlike quiz scores, which lie on an interval scale, likert items lie on an ordinal scale 
(Kumar, 2019). Rather than using the numbers assigned to likert items to estimate the exact 
probability of a respondent to get the vaccine, the numbers in likert scales are used to estimate 
respondents’ intentions toward vaccination as favorable or unfavorable. Thus, the sign test in this 
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case tests the statistical significance of the sample’s observed change in either direction (more 
likely to get vaccinated or less likely to get vaccinated), but there is no way to tell how much 
more likely or how much less likely. 
Finally, the pre- and post-video “intention to act on the issue” measures were compared 
within subgroups at different stages of the precaution adoption process as determined by answers 
to the question, “Please indicate which statement best indicates your thoughts about HPV 
vaccination today.” Microsoft Excel was used for descriptive statistical analysis and IBM SPSS 
26 was used for statistical significance tests. 
Results 
 One hundred fourteen surveys were started. Of these, 15 were excluded because the pre-
video questions were not answered. Twenty surveys were completed up to the video, with a 
minimum completion time of 82 seconds, thus none of these was excluded from the baseline 
analysis. There were 81 one surveys that were completed entirely. Of these, 13 were excluded 
from analysis because they were completed in less than 11 minutes. Thus, the first analysis 
included 20 surveys that were completed up to the video and 68 surveys that were completed 
entirely. The second analysis contained only the 68 surveys that were completed entirely. 
 The results of the baseline analysis are shown in table 1. The average pre-video quiz 
score was 15.09 (out of 25) for the entire sample, 16.64 for nursing students, 14.46 for non-
nursing students, 15.46 for cis-female respondents, 13.92 for cis-male respondents, and 13.43 for 
non-traditional gender students. Sixty-three percent of the sample had received at least one dose 
of the HPV vaccine, and 51% was fully vaccinated. Among nursing students, 72% had initiated 
HPV vaccination and 68% were fully vaccinated. Among non-nursing students, 59% had 
initiated HPV vaccination and 44% were fully vaccinated. Among cis-female respondents, 67% 
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had initiated HPV vaccination, and 54% were fully vaccinated. Among cis-male students, 33% 
had initiated HPV vaccination and 25% had completed HPV vaccination. Among non-traditional 
gender students, 71% were fully vaccinated and 29% were unvaccinated. 
 Pre-video HPV knowledge scores ranged from 1/25 to 24/25, with a mean of 15.40. Post-
video HPV knowledge scores ranged from 7/25 to 25/25, with a mean of 22.21. Sixty 
respondents had a higher score in their post-video questionnaire, six had the same scores in both 
questionnaires and two scored lower in the post-video questionnaire. The improvement in post-
video HPV knowledge scores was statistically significant with p < 0.001 (two-tailed). These 
results are summarized in table 2. 
 Table 3 shows the percentage of respondents who correctly answered the HPV 
knowledge questions in the pre- and post-video quizzes. All the knowledge questions had a 
higher percentage of correct answers in the post-video quiz. In the pre-video quiz only three 
questions were answered correctly by 90% or more of the respondents, whereas in the post-video 
quiz 18 questions were answered correctly by 90% or more of the respondents. There was visible 
improvement in most questions regarding HPV transmission mode, but 34% of respondents 
incorrectly believed that a person with no symptoms cannot transmit HPV infection after 
viewing the video. Thirty two percent and 50% believed that HPV can cause AIDS and herpes, 
respectively, after viewing the video. Only 79% and 60% of respondents correctly answered that 
the HPV vaccine prevents most cervical cancers and that the HPV vaccine prevents genital 
warts, respectively. Knowledge of HPV’s link with cervical and non-cervical cancers visibly 
improved.  
 Of the 68 respondents who finished the survey, 31 were either unvaccinated, partially 
vaccinated, or uncertain of their vaccination status, and thus were asked about their likelihood to 
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act on the issue of HPV vaccination, i.e., get the vaccine, finish their immunizations, or find out 
their status. In the pre-video questionnaire, two respondents (both unvaccinated) reported being 
very unlikely to get vaccinated, three were unlikely to act on the issue, five were undecided, 11 
were likely to act on the issue, and 10 were very likely to act on the issue. In the post-video 
questionnaire, the two respondents who were very unlikely to get vaccinated before viewing the 
video reported being extremely unlikely to get vaccinated after viewing the video. Two 
respondents were undecided after viewing the video, seven were somewhat likely to act on the 
issue, and 19 were extremely likely to act on the issue. No respondent chose the “somewhat 
unlikely option after viewing the video. One participant did not answer the post-video question 
regarding intention to act on the issue. Before viewing the video, 21 respondents were either 
likely or very likely to act on the issue, whereas after viewing the video 26 respondents were 
either somewhat likely or extremely likely to act on the issue. These results are summarized in 
table 4. (There was a minor flaw in the wording of the answer options for the questions on 
likelihood to act on the issue. Participants who were partially vaccinated and those who did not 
know their vaccination status saw the options “very unlikely,” “unlikely,” “undecided,” “likely” 
and “very likely” in this question before viewing the video, whereas unvaccinated participants 
saw the options “extremely unlikely,” “somewhat unlikely,” “undecided,” “somewhat likely” 
and “extremely likely.” In the post-video questionnaire, all the respondents saw the options 
“extremely unlikely,” “somewhat unlikely,” “uncertain,” “somewhat likely” and “extremely 
likely.” In the statistical analysis the questions were coded from 0 to 4, with 0 being least likely, 
2 neutral, and 4 most likely).  
 Of the 31 respondents who were asked about likelihood to act on the issue of HPV 
vaccination, one was less likely to act after viewing the video, 15 were more likely to act after 
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viewing the video, and 14 were just as likely to act before and after the video. This result was 
statistically significant based on a p value of 0.001 after application of a two-tailed sign test.  
Of the 68 respondents who finished the survey, 26 (11 who were unvaccinated, 11 who 
did not know if they had ever got an HPV immunization, and four who were vaccinated but did 
not know how many doses they’ve had) were asked about their stage in the precaution adoption 
process with the question, “please indicate which statement best indicates your thoughts about 
HPV vaccination today” (see Q33, appendix 1). Unfortunately, because of a flaw in the survey, 
respondents who were partially vaccinated and knew how many vaccine doses they had received 
were not asked about their stage in the precaution adoption process. Sixteen respondents had 
never seriously thought about getting the HPV vaccine, one had seriously thought about it but 
decided not to get it, three had seriously thought about the HPV vaccine sometime, but not in the 
last six months, five were seriously thinking about getting the HPV vaccine within six months, 
and one was planning to get the vaccine within one month. These results are summarized in table 
5. 
The determination of a respondent’s stage in the precaution adoption process based on his 
answer choice can be difficult. According to Barnard et al., a respondent who never seriously 
thought about getting the HPV vaccine is either unaware (stage 1) or unengaged (stage 2), and a 
respondent who has seriously thought about the HPV vaccine in the past but not in the last six 
months is deciding about getting the vaccine (stage 3). However, one can argue that such 
respondents could have forgotten about the issue and thus returned to stage 2 (unengaged). 
Barnard et al. interpret the answer choice “I am seriously thinking about getting the HPV vaccine 
sometime within the next six months” as an indicator of having decided to act (stage 5), but this 
could well be interpreted as still being undecided. Barnard et al. would classify a respondent who 
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plans to get the HPV vaccine within the next month as someone transitioning from stage 5 to 
stage 6 (acting). Based on the language used in these answer choices, in this analysis the answer 
choice “I never seriously thought about getting the HPV vaccine” is interpreted as the respondent 
being in either stage 1 or stage 2, and the answer choice “I have seriously thought about getting 
the HPV vaccination but decided not to get it” is interpreted as the respondent being in stage 4. 
But no attempt is made at equating any of the other answer choices to a particular stage in the 
precaution adoption process because there are many possible interpretations. Therefore, the only 
interpretation that can be made with confidence is that 16 respondents were either unaware or 
unengaged by the issue of HPV vaccination, and one had decided against getting the HPV 
vaccination.  
Of the sixteen respondents who were in stages 1 and 2, eight had a positive change in 
their likelihood to act on the issue of HPV vaccination after viewing the video, seven had no 
change in their likelihood to act on the issue, and one had a negative change in likelihood to act 
on the issue. After viewing the video, 13 respondents were either somewhat likely or extremely 
likely to act on the issue after viewing the video, compared to 10 before viewing the video. Not 
surprisingly, the one respondent who had decided against getting the HPV vaccine was very 
unlikely to get the vaccine both before and after viewing the video. In fact, according to 
Weinstein (1988) those who are unaware or unengaged have a more open mind regarding the 
issue, whereas those who have decided against acting may have difficulty in changing their 
stage.  
Of the three participants who had not thought about HPV vaccination in the last six 
months, one went from unlikely to act on the issue to extremely likely to act on the issue, one did 
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not change his original answer (likely to act on the issue), and one changed his answer from 
undecided to somewhat likely.  
Of the five participants who had seriously thought about getting the HPV vaccine within 
the next six months, three changed their answers from likely to extremely likely, one was very 
likely to act on the issue but did not answer the post-video question, and one did not change his 
original answer (very likely). The one participant who was planning on getting the HPV vaccine 
within the next month also answered very likely in the pre- and post-video question regarding 
likelihood to act on the issue.  
Discussion 
 Results from the baseline analysis were consistent with those from other studies that have 
found overall HPV vaccine uptake below the Healthy People 2030 target of 80%, with lower 
rates among males than females (Barnard et al., 2017; Koplas et al., 2019; LaJoie et al., 2018; 
Ragan et al., 2018). 
 Results from analysis of the individual quiz questions (table 3) revealed knowledge 
deficits similar to those found in other surveys, namely, confusing HPV with herpes, not 
knowing that HPV can cause non-cervical cancers, not knowing that the HPV vaccine can 
prevent most cervical cancers, and not knowing that people can get the HPV vaccine until age 26 
(Barnard et al., 2017; Fenkl et al., 2016; Garcia Jones, 2017; Poggio D’Errico et al., 2020; 
Fontenot et al., 2014; McBride & Singh, 2018; Kellogg et al., 2019). 
 Overall, participants’ knowledge in several areas of HPV knowledge improved after 
viewing the video. Improvements were seen in knowledge of modes of HPV transmission, 
outcomes of HPV infection (genital warts and cancer), susceptibility to HPV infection, the need 
to screen for cervical cancer even after immunization against HPV, number of doses required for 
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full immunization, and age eligibility to get the HPV vaccine. However, several knowledge 
deficits remained in a significant portion of respondents after viewing the video, namely, 
confusion between HPV, HIV and herpes, not knowing that asymptomatic individuals can 
transmit HPV infection, and not knowing that the HPV vaccine can protect against cervical 
cancer and genital warts. These points need to be emphasized in future educational interventions. 
 Most participants were more likely to act on the issue of HPV vaccination after viewing 
the video, a considerable portion were just as likely as before, and very few were less likely to 
act after viewing the video. Consistent with the precaution adoption process model, participants 
who were unaware or unengaged with the issue had a relatively high tendency to change their 
likelihood to act in a favorable direction.  
 The intervention and its evaluation had several limitations. Because the project was 
implemented at a private university, the intervention did not reach out to a representative sample 
of young adults eligible for catch-up HPV immunization. Moreover, the intervention was not 
preceded by an assessment of the knowledge needs and educational preferences of the target 
audience, and several knowledge deficits remained in a significant portion of participants even 
after viewing the video. 
 In evaluating the intervention, important demographic characteristics were not assessed, 
and thus possible disparities in HPV knowledge and HPV immunization within the community 
of SU students were not assessed. Additionally, the results must be interpreted with caution, 
especially those pertaining to stages of the precaution adoption process and participants’ 
likelihood to act on the issue. As Weinstein (1988) notes, an intention to act does not necessarily 
translate into a tendency to act, so it is difficult to know whether those who had a favorable 
change in their likelihood to act will in fact get their HPV immunization. Additionally, as 
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mentioned above (see pp. 24-25), the determination of a respondent’s stage in the precaution 
adoption process based on the answer choices to the question “please indicate which statement 
best indicates your thoughts about the HPV vaccine today” depends largely on interpretation. 
 Because the survey was anonymous, the age and eligibility of participants was not 
verified. Self-report can favor biased responses, some participants may have been inattentive to 
the video, and some may have carelessly answered at least some of the survey questions.  
 Nevertheless, the results of this analysis were promising in that most knowledge items 
were answered correctly after participants viewed the video, which suggests that at least some 
doubts and misperceptions about HPV and the HPV vaccine may have been clarified for most 
respondents. It was particularly reassuring that the proportion of correct answers to the question 
regarding vaccine eligibility increased from 56% to 96%, indicating that most viewers now know 
they are eligible for catch-up HPV immunization, and this may prompt them to get vaccinated.  
Implications for practice and recommendations for future work 
 As the precaution adoption process model asserts, and as it has been found in prior 
studies (Preston & Darrow, 2019; Staples et al., 2018) as well as this one, educational 
interventions can have a positive influence on individuals’ knowledge of vaccines and intentions 
to get vaccinated. Therefore, efforts must be made by clinicians to inform young adult patients 
about HPV and the HPV vaccine. Education about HPV should be carried out both in public 
health interventions to reach out to groups and in clinicians’ offices to reach out to individual 
patients. Just as college campuses are a convenient place to find young adults eligible for catch-
up HPV immunization, so are, for instance, youth homeless shelters. In addition to reaching out 
to young adults in as many settings as possible, multiple channels of information sharing must be 
employed. A college clinic can, for instance, send a reminder email with information on HPV to 
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new students each year. Informational posters can be placed in college clinic waiting rooms, 
libraries, and hang-out places.  
 As other studies have found (Holman et al., 2014; Lau, 2012; Reiter, 2013), a clinician’s 
recommendation can have a significant influence in patients’ decision to vaccinate, and 
therefore, clinicians should continue their efforts in recommending HPV—or any other—vaccine 
to eligible individuals. 
 In order to clarify misperceptions about HPV found in this and other surveys (Barnard et 
al., 2017; Fenkl et al., 2016; Garcia Jones, 2017; Poggio D’Errico et al., 2020; Fontenot et al., 
2014; McBride & Singh, 2018; Kellogg et al., 2019), and to increase young adults’ confidence in 
the HPV vaccine, future educational interventions should emphasize the following teaching 
points:  
● Men, women, non-binary, gender-fluid, cis and trans individuals are susceptible to HPV 
infection regardless of sexual orientation. 
● HPV can cause cervical cancer as well as cancers of the mouth, throat, penis and anus 
● If not vaccinated, most sexually active people will be infected with HPV at some time in 
their lives 
● An asymptomatic individual can transmit HPV infection 
● HPV can be transmitted through any skin-to-skin or mucosal contact 
● HPV, HIV, and herpes are different diseases caused by different viruses 
● The HPV vaccine protects against genital warts, most cervical cancers, and non-cervical 
HPV-associated cancers 
● HPV infection cannot be cured with vaccination against HPV 
● Even after vaccination, women must screen for cervical cancer 
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● Ideally, one should get the HPV vaccine before sexual debut, but there is time to catch up 
until age 26; and, depending on individual risk factors, individuals as old as 45 can 
vaccinate against HPV according to ACIP recommendations (Meites et al., 2019). 
While information sharing and education can play an important role in helping young 
adults catch-up with HPV immunization, these efforts need to be coordinated with other 
interventions that facilitate vaccine uptake in young adults. College clinics can, for instance, set 
up pop-up vaccination clinics at the beginning of each term, when students are not yet 
overwhelmed with final exams and more likely to pay attention to non-academic matters. 
Each of the interventions suggested above can be implemented and evaluated at a college 
campus. Future interventions and evaluations should take into account demographic factors such 
as race and ethnicity in order to identify and mitigate disparities in HPV knowledge and vaccine 
uptake. Qualitative evaluations may be more helpful in identifying young adults’ stages in the 
precaution adoption process, their reasons not to get vaccinated, and barriers to vaccine uptake. 
Interventions informed by a more thorough assessment of the target populations can be more 
effective in helping young adults overcome their specific barriers—real or perceived—to HPV 
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Table 1. Baseline HPV knowledge average scores (out of 25) and percentage of vaccinated 















score (out of 
25) 
Major       
     Nursing 25 6       
(24%) 
1     
(4%) 
18    
(72%) 
17     
(68%) 
16.640 






28    
(44.44%) 
14.476 
Gender       
     Cis-female 69 13   
(18.84%) 







     Cis-male 12 3    
(25%) 
5   
(41.67%) 
4  (33.33%) 3     
(25%) 
13.917 
    Non-binary or 
gender-fluid                


















Table 2. Knowledge scores in pre-video and post-video questionnaires; p < 0.001 as 
determined by two-tailed Wilcoxon sign test. 
Questionnaire Number of 
respondents 
Mean Median Standard 
deviation 
Minimum Maximum 
Pre-video 68 15.40 16.5 5.53 1 24 




Table 3. Percentage of respondents who answered correctly each question in the pre- and 
post-video quizzes. 




Human papillomavirus (HPV) can cause cervical cancer - 
True 
69 99 
HPV can be transmitted through genital skin-to-skin contact - 
True 
74 94 
There are many types of HPV - True 66 99 
HPV can cause HIV/AIDS - False 49 68 
HPV can be passed on during sexual intercourse - True 91 99 
HPV can cause genital warts - True 68 96 
Men can get HPV - True 90 97 
Having many sexual partners increases the risk of getting 
HPV - True 
91 100 
Most sexually active people will get HPV at some point in 
their lives - True 
26 82 
A person could have HPV for many years without knowing it 
- True 
81 97 
HPV can cause anal cancer - True 31 94 
HPV can be transmitted through oral sex - True 66 97 
HPV can cause cancer of the penis - True 35 94 
HPV can cause herpes - False 34 50 
HPV can be transmitted through anal sex - True 71 96 
HPV can cause throat and mouth cancer - True 35 93 
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Table 3 continued. Percentage of respondents who answered correctly each question in the 
pre- and post-video quizzes. 




A person with no symptoms cannot transmit the HPV infection - 
False 
65 66 
The HPV vaccine requires only one dose - False 56 96 
The HPV vaccine protects against all sexually transmitted 
infections - False 
84 97 
The HPV vaccine protects against most cervical cancers - True 53 79 
The HPV vaccine protects against genital warts - True 29 60 
Women who have had the HPV vaccine do not need to screen for 
cervical cancer - False 
85 97 
The HPV vaccine protects you from every type of HPV - False 51 90 
You can cure HPV by getting the HPV vaccine - False 84 87 
According to CDC guidelines, persons aged 18 - 26 are still on 












Table 4. Number of respondents who chose each of the options from least likely to most 
likely in the questions regarding intention to act on the issue of HPV vaccination, i.e., get 
vaccinated, get their remaining doses of the HPV vaccine, or find out their immunization 
status. In the statistical analysis, answer options were coded from 0 to 4, with 0 being most 
unlikely, 2 neutral, and 4 most likely. 
Answer choice to pre- and 
post-video question 
regarding intention to act 
Number of respondents who 
chose each answer before 
viewing video 
Number of respondents who 
chose each answer after 
viewing video 
Most unlikely (0) 2 2 
Somewhat unlikely (1) 3 0 
Neutral (2) 5 2 
Somewhat likely (1) 11 7 
Most likely (4) 10 19 














Table 5. Number of respondents who indicated each answer choice to the question 
regarding stage in the precaution adoption process. Stages corresponding to each answer 
choice are according to Bernard et al.’s (2017) interpretation. 
Please indicate which statement best indicates your 
thoughts about HPV vaccination today 
Number of Respondents 
I never seriously thought about getting the HPV 
vaccine (Stages 1 & 2) 
16 
I have seriously thought about getting the HPV 
vaccine, but decided not to get it (Stage 4) 
1 
I have seriously thought about getting the HPV 
vaccine, but have not thought about it in the past 6 
months (Stage 3) 
3 
I am seriously thinking about getting the HPV 
vaccine sometime within the next 6 months (Stage 5) 
5 
I plan to get the HPV vaccine within the next month 





























Appendix 1. Survey. 
Q0 Seattle UniversityConsent to Participate in Survey 
Project Title - Catching up with HPV immunization: An educational video for college 
students 
Principal Investigator: Behrooz R. Soleimani, RN – Seattle University College of 
NursingFaculty Advisor: Colleen Woolsey, PhD, ARNP – Seattle University College of 
Nursing  
You are being invited to participate in a survey to evaluate an educational video about human 
papillomavirus (HPV) for college students. You will be asked to complete a survey with 60 
questions and view a 10-minute video in the following order: 
o   25 True/False questions on HPV knowledge 
o   5 – 8 demographic and vaccination questions 
o   View 10-minute video 
o   The 25 True/False questions on HPV knowledge will be asked again to see if the video was 
helpful in clarifying key points about HPV 
o   1 or 2 additional questions 
Who can participate? 
All Seattle University students age 18 – 26. 
How much time will the survey take? 
Depending on your pace, this survey may take up to one hour to complete (video included). 
Because surveys are anonymous, there is no way to save the data and resume the survey at a later 
time, so I ask participants that they please complete the survey in one session. This study is 
being performed as partial fulfillment of the requirements for the Doctor of Nursing Practice 
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(DNP) degree at Seattle University, i.e., this is my graduation project.  
Participation in this survey is completely voluntary, and you may stop at any time without 
any consequences. I will not ask about any direct identifiers but will be asking your age range 
(not your exact age), sex at birth, gender, college major, and HPV vaccination status. I am asking 
about these data because HPV education benefits all people regardless of sex or gender, but some 
groups may be more informed about HPV than others.  
RISKS 
·       You may find some questions personal or upsetting. You can skip any questions you don’t 
want to answer or stop the survey entirely. 
·       Whenever you provide information online, your data could be intercepted (hacked). I am 
using a secure system to collect this data, but this risk cannot be completely eliminated. 
·       To minimize the risk of your data being seen by anyone who shouldn’t, I will make sure:-   
Data is anonymous. 
-   I will store all electronic data on the secure servers for the online survey software (Qualtrics).  
The data will be kept until May 30, 2021, when the analysis is finalized. After that, the data will 
be deleted.   
 BENEFITS: 
Benefits to survey participants include learning about HPV and how to prevent it. The results of 
this survey will be used to improve educational materials about HPV for young adult college 
students.  
PARTICIPATION IN SURVEY AND RAFFLE  
Participation in the survey will require no monetary cost to you. You will have the option of 
entering a raffle to win one of eight $25 Amazon gift cards. To enter the raffle, participants must 
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finish the survey. At the end of the survey, you will be redirected to a separate survey where you 
will provide your seattleu.edu email to enter the raffle. Because you will enter your email in a 
separate survey, it cannot be connected to your responses in the original survey. Participants who 
drop out of the survey before finishing will not be able to enter the raffle. Because surveys are 
anonymous, there is no way to save the data and resume the survey at a later time, so if you 
would like to enter the raffle, you need to complete the survey in one session. The survey will be 
available until March 12, 2021, and the raffle will be held on March 13. Winners of the $25 
Amazon gift cards will be notified after the raffle.  
Only I will have access to the information you provide as well as Dr. Colleen Woolsey, 
my faculty advisor at the college of nursing, Ms. Katie Harrison, ARNP, my clinical advisor at 
the Seattle University Student Health Center, and Mr. Chris Fiorello, director of Seattle 
University Wellness & Health Promotion. If we share our findings in publications or 
presentations, the results will be in aggregate (grouped) data, with no individual results. If you 
have any questions about this project, contact Behrooz Soleimani, RN, by email at 
soleiman@seattleu.edu or by phone at (425) 318-9809. If you have any questions about your 
rights as a survey participant, contact the SU Institutional Review Board at 206-296-2585 / 
irb@seattleu.edu  
Remember, your participation is completely voluntary, and you are free to 
withdraw at any time. You can participate in the survey if you are: 
·       at least 18 years old 
·       at most 26 years old 
·       a Seattle University student.  
By participating in this survey you indicate you have read and understood this 
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informed consent document, that you are at least 18 years old, you voluntarily choose to 
participate in this survey, and you agree with the conditions outlined in this document. Do 
you consent to participate in this survey? 
 Yes, I voluntarily choose to participate in this survey  (1) → Go to Q1 
 No, I do not wish to participate in this survey  (2)  → End of survey 
 
Q1 Human papillomavirus (HPV) can cause cervical cancer 
True                              False                      I Don't know   
Q2 HPV can be transmitted through genital skin-to-skin contact 
 True                   False             I Don't know   
Q3 There are many types of HPV 
 True               False            I Don't know   
Q4 HPV can cause HIV/AIDS 
 True              False            I Don't know   
Q5 HPV can be passed on during sexual intercourse 
 True              False             I Don't know   
Q6 HPV can cause genital warts 
 True              False             I Don't know   
 Q7 Men can get HPV 
 True               False            I Don't know   
Q8 Having many sexual partners increases the risk of getting HPV 




 Q9 Most sexually active people will get HPV at some point in their lives 
 True               False             I Don't know   
 Q10 A person could have HPV for many years without knowing it 
 True            False              I Don't know   
Q11 HPV can cause anal cancer 
 True            False              I Don't know   
Q12 HPV can be transmitted through oral sex 
 True           False               I Don't know    
Q13 HPV can cause cancer of the penis 
 True            False              I Don't know   
 Q14 HPV can cause herpes 
True            False              I Don't know   
 Q15 HPV can be transmitted through anal sex 
 True            False              I Don't know   
Q16 HPV can cause throat and mouth cancer 
True            False              I Don't know   
Q17 A person with no symptoms cannot transmit the HPV infection 
True            False              I Don't know   
Q18 The HPV vaccine requires only one dose 
True            False              I Don't know   
Q19 The HPV vaccine protects against all sexually transmitted infections 




Q20 The HPV vaccine protects against most cervical cancers 
True            False              I Don't know   
Q21 The HPV vaccine protects against genital warts 
True            False              I Don't know   
Q22 Women who have had the HPV vaccine do not need to screen for cervical cancer 
True            False              I Don't know   
Q23 The HPV vaccine protects you from every type of HPV 
True            False              I Don't know   
Q24 You can cure HPV by getting the HPV vaccine 
True            False              I Don't know   
 Q25 According to CDC guidelines, persons aged 18 - 26 are still on time to get the HPV vaccine 
 True            False              I Don't know   
Q26 Please indicate your gender 
 Male   
 Female   
 Non-binary / third gender   
 Gender-fluid  
 No gender   
 I'm not sure   
 Other   
 Prefer not to answer   
 Q27 Please indicate your sex assigned at birth 
 Male           Female   
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 Q28 Are you a nursing student? 
 Yes              No   
 Q29 Have you been vaccinated for HPV? 
 Yes  → Go to Q30 
 No  → Go to Q32 
 I don't know  → Go to 31u 
Q30 How many of the HPV vaccine shots have you received? 
One (You need two more shots)  → Go to Q31 
 Two shots before age 15 (You have competed the HPV vaccine series)  → Go to video 
 Two shots after age 15 (You need one more shot)  → Go to Q31 
 Three shots after age 15 (You have completed the HPV vaccine series) → Go to video 
 I don't know → Go to Q31u 
Q31 How likely are you to get the remaining shots to finish the vaccine series? 
 Very unlikely   
 Unlikely   
 Undecided   
 Likely   
 Very likely   







Q31u If you don't know your HPV vaccination status, you can do one of two things: 
1. Find out your vaccination status from your parents/doctor/medical records and get the 
remaining vaccine doses 
2. Start the vaccination shots from the beginning 
How likely are you to pursue either of these options? 
 Very likely   
 Likely   
 Undecided   
 Unlikely   
 Very unlikely   
ALL ANSWERS: SKIP TO QUESTION 33 
 Q32 How likely are you to get the HPV vaccine? (Question seen by participants who responded 
“no” to question “Have you been vaccinated against HPV?”) 
 Extremely likely   
 Somewhat likely   
 Undecided   
 Somewhat unlikely   
 Extremely unlikely   







Q33 Please indicate which statement best indicates your thoughts about HPV vaccination today 
 I never seriously thought about getting the HPV vaccine   
 I have seriously thought about getting the HPV vaccine, but decided not to get it   
 I have seriously thought about getting the HPV vaccine, but have not thought about it in the 
past 6 months   
 I am seriously thinking about getting the HPV vaccine sometime within the next 6 months   
 I plan to get the HPV vaccine within the next month   
 ALL ANSWER CHOICES: GO TO VIDEO 
  
Video. Please watch the following video completely. You will be able to advance to the next 
question once nine minutes have elapsed since you arrived at this question (that is, after having 
watched the video one time). Do not refresh this page; if you do, you will be redirected to the 
beginning of the survey.  
If the video is not displaying properly below, please open a new tab on your browser and copy 
the link https://youtu.be/HQGD9mwVr2E on the address bar to watch the video on YouTube. 
Once you have finished watching the video, return to the survey tab. 
 
Q34 HPV can cause cervical cancer 
 True            False              I Don't know   
 Q35 HPV can be transmitted through genital skin-to-skin contact 
True            False              I Don't know   
Q36 There are many types of HPV 
True            False              I Don't know   
56 
 
Q37 HPV can cause HIV/AIDS 
 True            False              I Don't know   
 Q38 HPV can be passed on during sexual intercourse 
 True            False              I Don't know   
Q39 HPV can cause genital warts 
True            False              I Don't know   
Q40 Men can get HPV 
True            False              I Don't know   
Q41 Having many sexual partners increases the risk of getting HPV 
True            False              I Don't know   
Q42 Most sexually active people will get HPV at some point in their lives 
True            False              I Don't know   
Q43 A person could have HPV for many years without knowing it 
 True            False              I Don't know   
Q44 HPV can cause anal cancer 
True            False              I Don't know   
Q45 HPV can be transmitted through oral sex 
 True            False              I Don't know   
Q46 HPV can cause cancer of the penis  
True            False              I Don't know   
Q47 HPV can cause herpes 




Q48 HPV can be transmitted through anal sex 
True            False              I Don't know   
Q49 HPV can cause throat and mouth cancer 
True            False              I Don't know   
Q50 A person with no symptoms cannot transmit the HPV infection 
True            False              I Don't know   
Q51 The HPV vaccine requires only one dose 
True            False              I Don't know   
Q52 The HPV vaccine protects against all sexually transmitted infections 
True            False              I Don't know   
Q53 The HPV vaccine protects against most cervical cancers 
True            False              I Don't know   
Q54 The HPV vaccine protects against genital warts 
True            False              I Don't know   
Q55 Women who have had the HPV vaccine do not need to screen for cervical cancer 
 True            False              I Don't know   
Q56 The HPV vaccine protects you from every type of HPV 
True            False              I Don't know   
Q57 You can cure HPV by getting the HPV vaccine 
 True            False              I Don't know   
Q58 According to CDC guidelines, persons aged 18 - 26 are still on time to get the HPV vaccine 





If How many of the HPV vaccine shots have you received? = One IS SELECTED 
Or How many of the HPV vaccine shots have you received? = Two shots after age 15 IS 
SELECTED 
Or How many of the HPV vaccine shots have you received? = I don't know IS SELECTED 
Or Have you been vaccinated for HPV? = Yes IS NOT SELECTED 
Q59 Having watched the video on HPV and HPV vaccination, how likely are you to get your 
HPV vaccination or get your remaining vaccine doses? 
 Extremely likely   
 Somewhat likely   
 Uncertain   
 Somewhat unlikely   
 Extremely unlikely  
Q60 How much new information did you learn from watching the video on HPV? 
 I did not learn anything new about HPV from the video  (4) 
 I learned some new information about HPV from the video  (5) 
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